Jinbo Biopharmaceutical

Jinbo Biopharmaceutical is a leading Chinese biotechnology company specializing in the development and industrialization of recombinant humanized collagen through synthetic biology. The company is globally recognized for its proprietary Protollagen technology, which produces functional recombinant humanized collagen type III with a triple helix structure identical to human collagen. Their product portfolio spans medical aesthetics, wound care, and gynecology, including the first recombinant humanized collagen injection approved by the NMPA for facial tissue augmentation. Jinbo Biopharmaceutical operates a large-scale manufacturing base and maintains a strong focus on regenerative medicine and high-end biomaterials.